Full Press Release Details
Concord Healthcare Announces Approval Granted
to the Application for the Proton Therapy Equipment Registration Certificate
December 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company")
(NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that
the National Medical Products Administration of the People's Republic of China has granted approval to the application for
the Registration Certificate for Medical Device for the proton therapy equipment (the "Registration Certificate") made by
the Company's equipment supplier on December 6, 2024.
previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Concord Cancer Center
("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has completed the installment
of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently
obtained the large medical equipment procurement license for its proton equipment in September 2024. Upon obtaining the approval
for the Registration Certificate, Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience
after necessary preparations.
Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of the Company listed on the Main Board of The Stock
Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, also announced on December 9, 2024 that the
approval for Registration Certificate was granted. The Company previously announced the listing of Concord Healthcare's H
shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible
through the HKSE's website at www.hkexnews.hk.
About Concord Medical
Concord Medical Services Holdings Limited is a
healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered
hospitals across China. For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider
in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions
through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full
spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists
and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related
services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related
services, including primarily sales and installing of medical equipment and software, management and technical support, and operating
Safe Harbor Statement
This announcement contains forward-looking statements.
These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results
to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Concord Medical Services Holdings Limited